MAKING-SCIENCE
Making Science, a technology company specialising in innovation and digital acceleration, has today announced the launch of Gauss Cookie Deprecation Impact Tool, the first and only solution on the market designed to measure in real time what impact the loss of third-party cookies will have on companies' conversion rate to sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122293551/en/
(Photo: Business Wire)
This innovative tool comes at a key moment for the industry, following the announcement of Google's elimination of third-party cookies, scheduled for the second half of 2024. The Gauss Cookie Deprecation Impact Tool will provide Making Science customers with accurate percentage data to confirm how this loss of information will affect their business. In other words, for the first time, companies will have access to an unprecedented assessment that provides real data on the percentage of users who visit websites and applications without cookies, corroborating the effect on their marketing strategies.
The tool has already yielded very significant data for a selection of Making Science clients, measuring that the absence of third-party cookies will lead to a 30% drop in their conversion rates.
Real-time data thanks to technological innovation
This new platform is essential for companies that want to be prepared for the cookieless transformation of the digital ecosystem. Thanks to technological innovation and high capabilities in data analysis, Making Science will enable organisations to effectively identify how to redesign their marketing strategies, and optimise their performance in the face of this changing landscape.
With this launch, Making Science reaffirms its pioneering position in the development of innovative technological solutions. José Antonio Martínez Aguilar, CEO and Founder of Making Science, comments: "Staying ahead in a constantly changing digital environment is not an easy task, for that, it is essential to bet on innovation every day. Undoubtedly, the key is to have the ability to anticipate and come up with solutions such as Gauss Cookie Deprecation Impact Tool. This solution not only responds to the challenge of the loss of third-party cookies, but also offers companies the opportunity to anticipate and make strategic decisions to face a new landscape based on first-party data".
Gauss, the origin of the cutting edge
This new tool from Making Science is part of Gauss, a suite of technology solutions based on First Party Data and Artificial Intelligence for decision-making in key marketing and sales processes.
About Making Science
Making Science is a digital acceleration company with more than 1200 employees and a presence and technological development in 14 markets: Spain, Portugal, Mexico, Colombia, France, Italy, UK, Ireland, Sweden, Denmark, Norway, Germany, Georgia and USA. As a consulting partner of Local Planet, the world's largest network of independent media agencies, Making Science offers digital, technology and performance marketing services to an international audience. The areas in which Making Science operates are digital marketing and MarTech, software and cloud and artificial intelligence and SaaS, with a firm commitment to innovation.
As part of its commitment to innovation, Making Science offers its clients end-to-end capabilities required for consulting, development, integration and maintenance of advanced IT solutions that offer maximum scalability, cost-effectiveness and efficiency. In addition, it has a global network of delivery hubs that drive job creation and the availability of highly qualified technological talent for the development of projects that accelerate transformation and modernization.
Making Science participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact and the Pledge1% initiative, supporting non-profit organisations in its community with a strong commitment that will have a great impact in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122293551/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 08:15:00 CET | Press release
*Consumer Electronics Show, January 6-9, Las Vegas, NV, USA Thales’ secure operating system (OS) supports Samsung's security chip, winner of the CES 2026 ‘Best Cybersecurity Innovation’ Award. The chip is the first embedded Secure Element (eSE) to integrate post-quantum cryptography (PQC), protecting devices against tomorrow’s quantum-enabled cyber threats. Thales’ quantum-resistant software and OS enable unmatched performance, energy efficiency and long-term data protection. Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 07:00:00 CET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom